It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.

NEW YORK – Eli Lilly on Monday said it will acquire in vivo CAR T-cell therapy developer Orna Therapeutics to strengthen its R&D work in genetic medicine and in vivo cell engineering.

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a ...

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective ...

GT Biopharma is set to begin a Phase I trial in mid-2026 of its B7-H3-targeting natural killer cell engager, after the US Food and Drug Administration cleared its investigational new drug application ...

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle ...